Related Experiment Video
Updated: Aug 1, 2026

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Commentary on Cohen et al.: Role of Clinical Factors in Precision Medicine Test to Predict Nonresponse to TNFi
Stanley Cohen1, Jeffrey R Curtis2, Theodore Mellors3
1Internal Medicine, Rheumatology Division, Metroplex Clinical Research Center, Dallas, TX, USA.
Abstract:
A 2021 study described the development and validation of a blood-based precision medicine test called the molecular signature response classifier (MSRC) that uses 23 features to identify rheumatoid arthritis (RA) patients who are likely nonresponders to tumor necrosis factor-α inhibitor (TNFi) therapy. Both the gene expression features and clinical components (sex, body mass index, patient global assessment, and anti-cyclic citrullinated protein) included in the MSRC were statistically significant contributors to MSRC results. In response to continued inquiries on this topic, we write this letter to provide additional insights into the contribution of clinical components to the MSRC on the Network-004 validation cohort.
Related Concept Videos
The JAK-STAT Signaling Pathway
Factors Affecting Drug Response: Overview
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenomics: Identification of New Drug Targets

